skills regarding: pharmacoepidemiology, Neurology, neurosciences, Psychiatry, psycopharmacology, oncology, Cardiology, oftalmology, Dermatology a real taste for national and international mobility. 2015-2017 pharmacoepidemiology and Pharmacovigilance european programme eu2p. University of bordeaux. the eu2p master is an academic post-graduate diploma in Pharmacovigilance and pharmacoepidemiology jointly delivered by the seven european academic bodies working together as eu2p partners, coordinated by the University of bordeaux ( pharmacology) and Laboratory hoffman la roche ag. 2011-2012:master 2 in neuropsicology and neurosciences. University pierre and marie curie, paris and University pierre mendes france, grenoble.
International Clinical Research Associate
Since January 2015
monitoring activities ( epidemiologic study) concerning non interventionnel prospective study to assess the safety profile of herceptin subcutaneus initiated in patients with her2-positive early breast Cancer. (oncology) hermione. laboratoires roche typical monitoring activities: principals activities performed concerning this study: initiation visits (12 centers in paris), monitoring safety visits (ecrfs), close-out visits and queries solving. o processing and follow-up of serious Adverse Events, o management of centres in accordance with the science)" rel="nofollow">Protocol, ich-gcp guidelines and local sops; Report Writing; close-out visits, o participation in international Investigator/monitor meetings; teleconferences, o preparation of study documents (synopsis, dispensing forms...). others monitoring-safety activities concerned studies in the field of gynaecology, Dermatology and Ophthalmology. Monitoring activities ( EPIDEMIOLOGIC STUDY) concerning non interventionnel prospective study to assess the safety profile of HERceptin subcutaneus initiated in patients with HER2-positive early breast cancer. (Oncology) HERmione. LABORATOIRES ROCHE Typical Monitoring activities: Principals activities performed concerning this study: Initiation visits (12 centers in Paris), monitoring safety visits (eCRFs), close-out visits and queries solving. o Processing and follow-up of Serious Adverse Events, o Management of centres in accordance with the protocol, ICH-GCP guidelines and local SOPs; report writing; Close-out visits, o Participation in international Investigator/Monitor Meetings; teleconferences, o Preparation of study documents (Synopsis, Dispensing Forms...). Others monitoring-safety activities concerned studies in the field of gynaecology, dermatology and ophthalmology.
HEAD: Drug Safety Utilization Study concerning the use of ACHEI and MEMANTINE in patients with ADDecember 2015 --- October 2016
-development of a Drug Safety utilization study concerning the drug utilization of achei and memantine in patients with alzheimer disease, residing in italy. this project has been developped in collaboration with the University autonoma of barcellona, the superior Health authority, iss in roma and with the collaboration of medical center for ad patients in sicily, italy.
Clinical Research Associate trainee ( CERC) Monitoring Safety traineeAugust 2014 --- November 2014
-management of Adverse Events and international regulations activities concerning Adverse Events. - submission and Communication with Ethics committees and Ethics committee, european Health authorities, - Training on Clinical research procedures (sops), ich, gcp, gvp
StudentJanuary 2014 --- January 2014
Vacancy. Recherche CliniqueSeptember 2012 --- September 2013
coordination and collaboration to the development of severals projects in Clinical research concerning memory's disorders.
University of Bordeaux- Eu2P European Program Pharmacovigilance and Pharmacoepidemiology. in from Université de Bordeaux in 2017
M2 in Neuroscience et Neuropsychologie from Université Pierre et Marie Curie (Paris VI) in 2012
Master 2 in Neuroscience et Neuropsychologie from Université Pierre Mendès-France (Grenoble II) in 2012